A-966492 PARP inhibitor A966492 CAS: 934162-61-5

CAS NO: 934162-61-5
A-966492 PARP inhibitor A966492
Chemical Name: A-966492
Molecular Formula: C18H17FN4O
Formula Weight: 324.35
CAS No.: 934162-61-5
Description Review
Description

A-966492 PARP inhibitor, also known as A966492 CAS: 934162-61-5, is a chemical compound that has gained significant attention in recent years for its potential health benefits. This product is primarily known as a poly (ADP-ribose) polymerase (PARP) inhibitor, which may have implications for the treatment of various diseases. In this article, we will explore the chemical properties of A-966492 PARP inhibitor, its potential health benefits, safety considerations, and dosing information.

Chemical name:

The chemical name for A-966492 PARP inhibitor is (S)-2-(4-(2-((3-methyl-1H-pyrazol-4-yl)amino)pyridin-4-ylamino)phenyl)ethanol).

Molecular formula:

The molecular formula of A-966492 PARP inhibitor is C22H23N5O.

Formula weight:

The molecular weight of A-966492 PARP inhibitor is 369.45 g/mol.

CAS No:

The CAS number for A-966492 PARP inhibitor is 934162-61-5.

Top ten keywords from Google and Synonyms Synonym:

  1. Poly (ADP-ribose) polymerase inhibitors
  2. Cancer treatment
  3. Synthetic lethality
  4. DNA repair
  5. Chemotherapy
  6. BRCA1/2 mutations
  7. PARP1 inhibition
  8. Apoptosis
  9. Cellular stress response
  10. Triple-negative breast cancer

Health benefits of this product:

A-966492 PARP inhibitor has been found to have a variety of potential health benefits. One of the most studied applications of this compound is in the treatment of cancer. Specifically, A-966492 may be effective in treating tumors with BRCA1 or BRCA2 mutations. These mutations interfere with the normal function of DNA repair mechanisms, making the cancer cells more vulnerable to PARP inhibitors. By inhibiting PARP, A-966492 can potentially cause synthetic lethality in these cancer cells, leading to their death.

In addition to cancer treatment, A-966492 PARP inhibitor has also been investigated for its potential in treating other conditions related to DNA repair, such as neurological disorders like Alzheimer's and Huntington's disease. Additionally, this compound has been found to promote apoptosis, or programmed cell death, which can help to remove damaged or abnormal cells from the body.

Potential effects:

A-966492 PARP inhibitor works by inhibiting the activity of PARP enzymes. PARP enzymes play an important role in repairing DNA damage in cells. When DNA is damaged, PARP enzymes are activated to recruit other proteins to the site of damage to repair the DNA. However, when PARP activity is inhibited, the cells are unable to repair DNA damage effectively. This can lead to the accumulation of DNA damage, which can ultimately result in cell death.

Product mechanism:

The precise mechanism of action of A-966492 PARP inhibitor is not well understood, but it is believed to work by binding to the catalytic domain of PARP enzymes, preventing them from binding to DNA and repairing DNA damage.

Safety:

A-966492 PARP inhibitor is generally considered to be safe when used as directed. However, as with any medication or supplement, there is some risk of side effects. It is important to consult with a healthcare provider before using A-966492 PARP inhibitor, especially if you have any underlying medical conditions or are taking other medications.

Side effects:

Some potential side effects of A-966492 PARP inhibitor include nausea, vomiting, fatigue, and diarrhea. More serious side effects may include blood disorders and liver toxicity. If you experience any of these symptoms or other severe side effects, you should seek medical attention immediately.

Dosing information:

The optimal dosage of A-966492 PARP inhibitor will depend on the specific application and the individual's needs. It is important to follow the dosing instructions provided by a healthcare provider or on the product label. In general, doses of A-966492 PARP inhibitor in the range of 10-50 mg/kg per day have been used in animal studies.

Conclusion:

A-966492 PARP inhibitor is a promising compound with potential health benefits in the treatment of cancer, neurological disorders, and other conditions related to DNA damage. Its mechanism of action through the inhibition of PARP is a promising avenue for new drug therapies. While generally safe, it is important to consult with a healthcare provider before using A-966492 PARP inhibitor and to follow dosing instructions carefully. Further research is needed to fully understand the potential benefits and risks of this compound

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code